Artiva Biotherapeutics is a pre-revenue biotech with quality metrics below the engine's floor and a rejected analyst target, but heavy recent insider buying and a technical breakout offer a bullish counter-signal.
Thesis pillars
- Quality Below Engine Floor→Stable
- Heavy Insider Buying→Stable
- Technical Breakout Momentum→Stable
- +2 more pillars — see the Why tab for full reasoning
Artiva Biotherapeutics, Inc. (ARTV) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.03: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality.
Artiva Biotherapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies licensed from strategic partner GC Cell. Its lead candidate, AlloNK, is being evaluated with B-cell-targeted monoclonal antibodies across... Read more
Sell if holding. Engine safety override at $10.03: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 55, MACD bullish. Score 4.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Artiva Biotherapeutics, Inc.
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics is advancing AlloNK, an off-the-shelf, allogeneic natural killer cell therapy combined with B-cell-targeted monoclonal antibodies, across three clinical trials in B-cell-driven autoimmune diseases, prioritizing refractory rheumatoid arthritis, with initial dose-level response data expected in the first half of 2026. The company has no approved products, reported a $330.5 million accumulated deficit as of December 31, 2025, and held $108.0 million in cash expected to fund operations into the second quarter of 2027.
Artiva generates no product revenue; its entire model rests on a strategic partnership with GC Cell, a Republic of Korea cell-therapy company from which Artiva spun out in 2019 and which has spent over a decade developing the cord-blood-derived NK cell manufacturing process AlloNK uses. Manufacturing occurs at a 9,000-square-foot cGMP facility in San Diego capable of supplying roughly 1,000 patients annually at a projected commercial cost of goods of $3,000 to $12,000 per patient, an order of magnitude below the estimated $100,000-plus cost of autologous CAR-T. Beyond AlloNK, Artiva holds ex-APAC rights to two preclinical CAR-NK candidates, AB-201 (HER2-targeted) and AB-205 (CD5-targeted), and previously partnered with Affimed GmbH on a CD30-targeted NK-cell-engager trial in Hodgkin lymphoma before terminating that collaboration in July 2025 after Affimed filed for insolvency in May 2025.
Show full overview
Artiva is substantially dependent on AlloNK's clinical success, since every other internally developed program remains in preclinical or discovery stages and its one prior partnered clinical asset, the Affimed collaboration in Hodgkin lymphoma, ended when Affimed filed for insolvency in May 2025. That concentration is compounded by a platform bet: because all of Artiva's programs share the same NK cell manufacturing process licensed from GC Cell, a manufacturing, safety, or efficacy setback in the ongoing refractory RA or lupus nephritis trials could impair the perceived value of the entire pipeline at once. With initial refractory RA response data due in the first half of 2026 alongside planned FDA discussions on pivotal trial design, that single readout functions as the near-term catalyst for the whole company.
See also: Healthcare · Biotechnology
From Artiva Biotherapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineAlloNK10-K Item 1A: 'We are substantially dependent on the success of our lead product candidate, AlloNK, which is in clinical development.'
Material Events(8-K, last 90d)
- 2026-05-19Item 5.02HIGHCFO Thad Huston separated from the company effective May 22, 2026; the company plans a search for his replacement, with no successor named. Not the result of any dispute.SEC filing →
- 2026-05-19Item 5.02LOWDirector Diego Miralles, M.D. resigned from the Board effective May 18, 2026 in connection with his appointment as President and Head of R&D; board size reduced from eight to seven members; no dispute cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.03: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 55, MACD bullish. Prior stop was $9.33. Score 4.5/10, moderate confidence.
Take-profit target: $11.07 (+10.4% upside). Prior stop was $9.33. Stop-loss: $9.33.
Concentration risk — Pipeline: AlloNK; DATA_ISSUE: analyst_target_implausible (raw $35.80 vs price $10.03 — ratio 3.6×). Rejected, falling back to technical TP.; Quality below floor (1.6 < 4.0).
Artiva Biotherapeutics, Inc. trades at a P/E of N/A (forward -3.6). TrendMatrix value score: 5.0/10. Verdict: Sell.
12 analysts cover ARTV with a consensus score of 4.3/5. Average price target: $36.
What does Artiva Biotherapeutics, Inc. do?Artiva Biotherapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer...
Artiva Biotherapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies licensed from strategic partner GC Cell. Its lead candidate, AlloNK, is being evaluated with B-cell-targeted monoclonal antibodies across three clinical trials for B-cell-driven autoimmune diseases, prioritizing refractory rheumatoid arthritis, and the company has no approved products, an accumulated deficit of $330.5 million as of December 31, 2025, and $108.0 million in cash expected to fund operations into the second quarter of 2027.